{"nctId":"NCT01222520","briefTitle":"Telmisartan 80mg Non-responder Trial","startDateStruct":{"date":"2010-10"},"conditions":["Hypertension"],"count":174,"armGroups":[{"label":"Telmisartan and amlodipine FDC","type":"EXPERIMENTAL","interventionNames":["Drug: Telmisartan and amlodipine"]},{"label":"Telmisartan monotherapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Telmisartan"]}],"interventions":[{"name":"Telmisartan and amlodipine","otherNames":[]},{"name":"Telmisartan","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Essential hypertensive patients\n\n  * If already taking antihypertensive drugs, mean seated diastolic blood pressure (DBP) must be \\>=90 and \\>=114 mmHg\n  * If not taking any antihypertensive drugs, mean seated DBP must be \\>=95 and \\>=114 mmHg\n* Able to stop all current antihypertensive drugs without risk to the patient based on the investigators opinion.\n\nExclusion criteria:\n\n* Patients taking 3 or more antihypertensive drugs at signing the informed consent form\n* Patients with known or suspected secondary hypertension\n* Patients with clinically relevant cardiac arrhythmia\n* Congestive heart failure with New York Heart Association (NYHA) functional class III-IV\n* Patients with recent cardiovascular events\n* Patients with a history of stroke or transient ischaemic attack within last 6 months before signing the informed consent form\n* Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors; or patients with post-renal transplant or post-nephrectomy\n* Patients who have previously experienced characteristic symptoms of angioedema (such as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment with ARBs or ACE inhibitors\n* Patients with known hypersensitivity to any component of the investigational product, or a known hypersensitivity to dihydropyridine-derived drugs\n* Patients with hepatic and/or renal dysfunction\n* Pre-menopausal women who are nursing or pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough","description":"Reference baseline: Status of patients after the 8-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.28","spread":"0.73"},{"groupId":"OG001","value":"3.14","spread":"0.74"}]}]}]},{"type":"SECONDARY","title":"Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough","description":"Reference baseline: Status of patients after the 8-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.37","spread":"1.10"},{"groupId":"OG001","value":"3.49","spread":"1.10"}]}]}]},{"type":"SECONDARY","title":"Seated DBP Control Rate at Trough","description":"DBP control rate: The rate of patients with controlled seated DBP at trough of less than 90 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.9","spread":null},{"groupId":"OG001","value":"73.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.1","spread":null},{"groupId":"OG001","value":"26.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Seated SBP Control Rate at Trough","description":"SBP control rate: The rate of patients with controlled seated SBP at trough of less than 140 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.0","spread":null},{"groupId":"OG001","value":"71.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.0","spread":null},{"groupId":"OG001","value":"28.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Seated DBP Response Rate at Trough","description":"DBP response rate: The rate of patients who achieved an adequate response in seated DBP at trough (\\<90 mmHg and/or reduction from reference baseline ≥10 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":null},{"groupId":"OG001","value":"69.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.5","spread":null},{"groupId":"OG001","value":"30.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Seated SBP Response Rate at Trough","description":"SBP response rate: The rate of patients who achieved an adequate response in seated SBP at trough (\\<140 mmHg and/or reduction from reference baseline ≥20 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"48.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.5","spread":null},{"groupId":"OG001","value":"51.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Seated Blood Pressure (BP) Normalisation at Trough","description":"Seated blood pressure (BP) normalisation: The numbers of patients whose blood pressure was within normalisation criterion in terms of seated blood pressure after the 8-week double-blind period At trough: 24-hour post-dosing","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":87},"commonTop":["Nasopharyngitis"]}}}